ClinicalTrials.gg

Program

susineridine

Also written as “YZJ-4729”, “YZJ-4729 Tartrate injection” and “Experimental: YZJ-4729”.

Its studies are mostly in Pain, led by Shanghai Haiyan Pharmaceutical Technology.

Furthest: phase 3, since Mar 11, 20254 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Haiyan Pharmaceutical Technology41 open or runningphase 3since Mar 11, 2025Oct 31, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2024First study: phase 1 study in Postoperative AnalgesiaFirst studyNCT06681493 · 66 enrolled · China
  2. Nov 1, 2024Phase 2 study in PainNCT06680466 · 179 enrolled · China
  3. Mar 11, 2025Phase 3 study in PainNCT06890533 · 560 enrolled · China
  4. Mar 24, 2025Phase 2 study in PainNCT06901830 · 150 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06901830Pain · China2CompletedDec 6, 2025150
NCT06890533Pain · China3Active, not recruitingApr 17, 2026560
NCT06680466Pain · China2CompletedJul 15, 2024179
NCT06681493Postoperative Analgesia · China1CompletedApr 14, 202366

How it is read

Names in the registry

  • “YZJ-4729”, 5 entries
  • “YZJ-4729 Tartrate injection”, 1 entry
  • “Experimental: YZJ-4729”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.